cilia and flagella associated protein 298Genealiases: C21orf48 · C21orf59 · CILD26 · DNAAF16 · FBB18 · Kur
Q-omics provides the consensus-scored CFAP298 profile across patient tissues and cancer cell-line models. CFAP298 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CFAP298 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, CFAP298 protein abundance shows 20,084 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, BLCA, and PDAC as cancer lineages where CFAP298 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFAP298 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFAP298 survival associations across molecular data types. CFAP298 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFAP298 RNA expression–survival associations across cancer types. High CFAP298 expression shows unfavorable associations in KIRC, UVM, ACC, LGG, LIHC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CFAP298 RNA expression.
This table summarizes CFAP298 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CFAP298. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFAP298 shows lower tumor expression in KICH and higher tumor expression in BLCA, COAD, LIHC, STAD and BRCA. The BLCA box plot shows higher CFAP298 RNA expression in tumor versus normal tissue (log2 FC = +1.034, t-test p < 0.001).
This table shows molecular features associated with CFAP298 in patient tissues and cancer cell lines. In patient samples, CFAP298 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CFAP298 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
